SC
VNDA icon

Schulhoff & Co’s Vanda Pharmaceuticals VNDA Stock Holding History

Schulhoff & Co’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-38,500
Closed -$218K – 131
2024
Q2 		$218K Hold
38,500
– – 0.1% 118
2024
Q1 		$158K Buy
+38,500
New +$154K 0.07% 123

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Schulhoff & Co's VNDA Position: Q3 2024 in Review

Schulhoff & Co sold out of Vanda Pharmaceuticals (VNDA) in Q3 2024, closing a stake of 38,500 shares — an estimated $218K sold.

Schulhoff & Co first reported a position in VNDA in Q1 2024 and held it in 2 quarters. The position peaked at $218K in Q2 2024. 152 funds tracked by Wall St. Rank hold VNDA as of Q3 2024.

  • Schulhoff & Co reported no remaining Vanda Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Schulhoff & Co sold 38,500 Vanda Pharmaceuticals shares in Q3 2024, an estimated $218K.
  • Schulhoff & Co first reported a position in Vanda Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Schulhoff & Co's Vanda Pharmaceuticals position peaked at $218K in Q2 2024.
  • 152 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2024.

Based on Schulhoff & Co's 13F filing for Q3 2024, filed 6 Nov 2024.